January 22, 2014
At a press conference held after a Cabinet meeting on January 21, Health Minister Norihisa Tamura expressed “extreme disappointment” over the incidence of the investigator-initiated trial, called “Sign,” of Novartis Pharma’s tyrosine kinase inhibitor Tasigna (nilotinib), in which the company’s...read more